Individualised patient treatment approaches demand precise determination of initial disease extent combined with early, accurate
assessment of response to treatment, which is made possible by positron emission tomography/computed tomography (PET/CT). PET is a
non-invasive tool that provides tomographic images and quantitative parameters of perfusion, cell viability, proliferation and/or metabolic
activity of tissues. Fusion of the functional information with the morphological detail provided by CT as PET/CT can provide clinicians
with a sensitive and accurate one-step whole-body diagnostic and prognostic tool, which directs and changes patient management. Three
large-scale national studies published by the National Oncologic PET Registry in the USA have shown that imaging with PET changes
the intended patient management strategy in 36.5% to 49% of cases, with consistent results across all cancer types. The proven clinical
effectiveness and growing importance of PET/CT have prompted the College of Nuclear Physicians of South Africa, in collaboration
with university hospitals, to develop a list of recommendations on the appropriate use of fluorine-18-fluorodeoxyglucose (18F-FDG) and
non-18F-FDG PET/CT in oncology, cardiology, neurology and infection/inflammation. It is expected that other clinical situations will be
added to these recommendations, provided that they are based upon solid clinical evidence. These recommendations are intended to offer
advice regarding contemporary applications of PET/CT, as well as indicating novel developments and potential future indications. The
CNP believes that these recommendations will serve an important and relevant role in advising referring physicians on the appropriate use
of 18F-FDG and non-18F-FDG PET/CT. More promising clinical applications will be possible in the future, as newer PET tracers become
more readily available.
Minne, Cornelia; Kisansa, Margaret E.; Ebrahim, Nazeema; Suleman, Farhana Ebrahim; Makhanya, Nonjabulo Ziphano(Health and Medical Publishing Group, 2014-08-01)
BACKGROUND: Even though magnetic resonance imaging (MRI) is the gold standard investigation
for intracranial pathology, it is not widely available in developing countries and computed
tomography (CT) of the brain remains ...
Vorster, Mariza; Doruyter, A.; Brink, A.; Mkhize, S.; Holness, J.; Malan, N.; Nyakale, Nozipho E.; Warwick, J.M.; Sathekge, Mike Machaba(Health and Medical Publishing Group, 2016-01)
These recommendations are intended to serve an important and relevant role in advising referring physicians on the appropriate use
of 18F-fluorodeoxyglucose (18F-FDG) and non-18F-FDG positron emission tomography/computed ...
Ebenhan, Thomas; Schoeman, Isabel; Rossouw, Daniel D.; Grobler, Anne; Marjanovic-Painter, Biljana; Wagener, Judith; Kruger, Hendrik G.; Sathekge, Mike Machaba; Zeevaart, Jan Rijn(Springer, 2017-06)
PURPOSE : Radiopharmaceuticals containing the motive tripeptide arginyl-glycyl-asparatic acid (RGD) are known to target ανβ3 integrins during tumor angiogenesis. A more generic kit radiolabeling procedure accommodating ...